On the public citation graph

The Small Molecular Compound CC1007 Suppresses Multiple Myeloma Via Upregulation of Nur77

https://doi.org/10.2139/ssrn.4189784
0 signed · 32 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/s12185-016-2008-0openalex-extracted
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside
inferredcites →https://doi.org/10.1016/j.canlet.2013.01.025openalex-extracted
A novel CyclinE/CyclinA-CDK Inhibitor targets p27Kip1 degradation, cell cycle progression and cell survival: Implications in cancer therapy
inferredcites →https://doi.org/10.1016/j.ctrv.2018.09.001openalex-extracted
Drug resistance in multiple myeloma
inferredcites →https://doi.org/10.1016/j.mcn.2010.01.012openalex-extracted
MEF-2 regulates activity-dependent spine loss in striatopallidal medium spiny neurons
inferredcites →https://doi.org/10.1016/s0092-8674(04)00162-xopenalex-extracted
Conversion of Bcl-2 from Protector to Killer by Interaction with Nuclear Orphan Receptor Nur77/TR3
inferredcites →https://doi.org/10.1016/s0140-6736(21)00135-5openalex-extracted
Multiple myeloma
inferredcites →https://doi.org/10.1016/s1470-2045(14)70440-1openalex-extracted
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
inferredcites →https://doi.org/10.1038/bcj.2014.29openalex-extracted
The role of epigenetics in the biology of multiple myeloma
inferredcites →https://doi.org/10.1038/bjc.2013.392openalex-extracted
Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
inferredcites →https://doi.org/10.1038/leu.2015.83openalex-extracted
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma
inferredcites →https://doi.org/10.1038/nchembio.313openalex-extracted
Chemical phylogenetics of histone deacetylases
inferredcites →https://doi.org/10.1038/nm1579openalex-extracted
Abrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia
inferredcites →https://doi.org/10.1038/nrc.2017.63openalex-extracted
Evolutionary biology of high-risk multiple myeloma
inferredcites →https://doi.org/10.1038/s41388-020-1158-yopenalex-extracted
Nur77-activated lncRNA WFDC21P attenuates hepatocarcinogenesis via modulating glycolysis
inferredcites →https://doi.org/10.1038/s41419-020-02949-1openalex-extracted
A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1− pre-B-ALL
inferredcites →https://doi.org/10.1038/sj.leu.2405067openalex-extracted
MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines
inferredcites →https://doi.org/10.1046/j.1365-2184.2003.00266.xopenalex-extracted
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
inferredcites →https://doi.org/10.1073/pnas.0503221102openalex-extracted
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
inferredcites →https://doi.org/10.1080/10428194.2017.1312383openalex-extracted
MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated withCDKN1Bdeletions and a poor response to glucocorticoid therapy
inferredcites →https://doi.org/10.1093/nar/gks189openalex-extracted
Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2
inferredcites →https://doi.org/10.1111/bjh.16418openalex-extracted
High expression of myocyte enhancer factor 2C predicts poor prognosis for adult acute myeloid leukaemia with normal karyotype
inferredcites →https://doi.org/10.1111/imr.12233openalex-extracted
Targeting the bone marrow microenvironment in multiple myeloma
inferredcites →https://doi.org/10.1111/nyas.12578openalex-extracted
The osteoblastic niche in the context of multiple myeloma
inferredcites →https://doi.org/10.1136/gutjnl-2011-300783openalex-extracted
The orphan receptor TR3 suppresses intestinal tumorigenesis in mice by downregulating Wnt signalling
inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-2526openalex-extracted
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
inferredcites →https://doi.org/10.1182/blood-2002-11-3514openalex-extracted
Molecular sequelae of histone deacetylase inhibition in human malignant B cells
inferredcites →https://doi.org/10.1182/blood-2006-11-056879openalex-extracted
Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma
inferredcites →https://doi.org/10.1182/blood-2011-10-387365openalex-extracted
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
inferredcites →https://doi.org/10.1182/blood-2013-08-518878openalex-extracted
NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas
inferredcites →https://doi.org/10.1186/s13045-018-0654-9openalex-extracted
Histone deacetylase 6 in cancer
inferredcites →https://doi.org/10.3322/caac.21494openalex-extracted
Cancer Statistics for Hispanics/Latinos, 2018
inferredcites →https://doi.org/10.4161/15592294.2014.983367openalex-extracted
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.